Merus N.V. (MRUS) Receives $30.25 Average Price Target from Analysts
Merus N.V. (NASDAQ:MRUS) has received an average recommendation of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.25.
MRUS has been the subject of a number of recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and set a $31.00 target price on shares of Merus N.V. in a research report on Friday, July 14th. Zacks Investment Research cut shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Saturday, July 15th. Royal Bank Of Canada initiated coverage on shares of Merus N.V. in a research report on Thursday, September 14th. They set an “outperform” rating and a $28.00 target price for the company. Finally, ValuEngine cut shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd.
A hedge fund recently bought a new stake in Merus N.V. stock. Renaissance Technologies LLC bought a new position in shares of Merus N.V. (NASDAQ:MRUS) in the first quarter, according to the company in its most recent filing with the SEC. The firm bought 22,500 shares of the biotechnology company’s stock, valued at approximately $549,000. Renaissance Technologies LLC owned approximately 0.14% of Merus N.V. as of its most recent SEC filing. Institutional investors own 31.52% of the company’s stock.
Shares of Merus N.V. (NASDAQ MRUS) opened at $15.42 on Friday.
Merus N.V. Company Profile
Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.